Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: bevacizumab|DRUG: Paclitaxel
Sponsor: Eastern Cooperative Oncology Group
Collaborators: National Cancer Institute (NCI)|North Central Cancer Treatment Group|NCIC Clinical Trials Group|NSABP Foundation Inc